ClinicalTrials.gg
RecruitingNCT07447687STOPUpdated Oct 20, 2026

Soy Tomato Juice to Improve Outcomes in Pancreatitis

A Phase 1/2 interventional study of Soy-tomato juice product and Will include a soy-tomato juice product to be consumed during the 4 week intervention phase. A total of about 12 ounces (administered in two small cans) of the juice will be consumed in Recurrent Acute Pancreatitis and Chronic Pancreatitis, sponsored by Ohio State University. Recruiting at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-20.

Primary conditionPancreatitis, ChronicRegistry: PancreatitisReclassifiedWhy we changed it
Registry
Pancreatitis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Pancreatitis, Chronic
Why
  1. The study's listed conditions name Pancreatitis, Chronic, a narrower term within Pancreatitis.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Ohio State University · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.
Updated Oct 20, 2026Start date movedPrimary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
35
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 111 studies in Pancreatitis, Chronic with a site in United States — 27 open to participants now, 38 under way, none of them phase 3. Pancreatitis, Chronic · United States.

Planned enrollment
36th of 73
35 · median 32
Started
2026
with 7 others
Phase 1/2
7 of 111
2 open now
Primary completion
2028-01
later than 24 of 37 live
Registered
106th of 111
by date
Lead sponsor
4 of 111
Ohio State University

Among the 111 studies in Pancreatitis, Chronic with a site in United States, this one is the 36th largest by planned enrollment of the 73 interventional ones that give a count, is one of 8 that started in 2026, is one of 7 in phase 1/2, reaches primary completion later than 24 of the 37 other live ones, and was the 106th registered.

Pancreatitis, Chronic

266 studies on the registry are indexed under Pancreatitis, Chronic; 76 are open to participants now.

Browse Pancreatitis, Chronic studies →

Open to participants now

27 of the 111 studies in Pancreatitis, Chronic with a site in United States are open now. Recruiting first, the newest first:

21 more — sign in →

All 27 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 49 Pancreatitis, Chronic studies recruiting now, 31 (63%) set no upper age limit and 12 (24%) stop at 75 or younger; 8 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 111 studies in Pancreatitis, Chronic with a site in United States, or all of them as a file.
02

Study summary

This goal of this clinical trial is to see if people with recurrent acute pancreatitis or chronic pancreatitis can tolerate and regularly drink a tomato juice beverage. Researchers will also measure inflammation and ask participants to report how they feel. Everyone in the study will receive the tomato juice drink, and both participants and researchers will know what is being taken. The investigators expect the drink will be well tolerated, may lower inflammation, and may improve participant-reported symptoms and quality of life.

Read the detailed description

This is a pilot, single arm, open label clinical trial to assess the tolerability and compliance of a soy-tomato juice dietary intervention in participants with recurrent acute pancreatitis (RAP) / chronic pancreatitis (CP) and evaluate the effects of the diet on inflammation and patient-reported outcomes (PROs). The investigators hypothesize this diet will be well tolerated, reduce measures of systemic inflammation, and potentially improve PROs.

During the trial, participants will complete a 4-week run-in phase where they are asked to consume a modified diet low in soy and lycopene. Then, participants will be provided a soy-tomato juice product to be consumed during the 4-week intervention phase. A total of about 12 ounces (administered in two small cans) of the juice will be consumed daily.

03

Conditions studied

  • Recurrent Acute Pancreatitis
  • Chronic Pancreatitis

Browse trials for

Keywords

  • Soy
  • Tomato
  • Dietary Intervention
  • abdominal pain
  • inflammation
  • lycopene
  • soy isoflavones
  • anti-inflammatory diet
  • medical nutrition
  • diet
  • Ohio State University
04

In context

Pancreatitis, Chronic Reclassified

266 studies on the registry are indexed under Pancreatitis, Chronic; 76 are open to participants now.

This study's planned enrollment of 35 is below the median of 47 across 142 interventional studies indexed under Pancreatitis, Chronic.

Browse Pancreatitis, Chronic studies →

Lead sponsor

Ohio State University is the lead sponsor of 664 studies on the registry; 149 are open to participants now.

Of its 67 completed or terminated interventional studies of FDA-regulated products, 49 (73%) have results posted.

Compared within Pancreatitis, Chronic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Pancreatitis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of definite chronic pancreatitis (CP) or recurrent acute pancreatitis (RAP)
  • Patients should be able to fully understand and participate in all aspects of the study

Exclusion criteria

Exclusion Criteria:

  • Episode of acute pancreatitis, hospitalization, or endoscopic/surgical intervention within 30 days of enrollment
  • Chronic, daily use of systemic immunomodulatory medication for any indication
  • Previous allergic reaction to soy or tomato products
  • Known pregnancy
06

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
35 participants (estimated)

Study arms

  • Experimental
    soy-tomato juice

    4 week run-in phase where they are asked to consume a diet low in soy and lycopene, then they will receive the intervention for 4 weeks.

    Dietary Supplement: Soy-tomato juice product · Dietary Supplement: Will include a soy-tomato juice product to be consumed during the 4 week intervention phase. A total of about 12 ounces (administered in two small cans) of the juice will be consumed

Interventions

  • Dietary supplementSoy-tomato juice product

    A high lycopene tomato (with levels 2-3x higher than typical) will be grown at OSU farms, as we have done previously. Tomatoes will be harvested and transported to OSU's Food Industries Center (Columbus, OH) for processing into juice and canned using commercial methods. A soy isoflavone extract will be acquired from a commercial supplier, tested for isoflavone content, and dosed into the juice before canning. Our juice recipe has been formulated and previously tested to ensure palatability. Proximate analysis (i.e., the information found on a nutrition facts panel) will be collected from our final juice, along with carotenoid and soy isoflavone levels to fully characterize our intervention agent.

  • Dietary supplementWill include a soy-tomato juice product to be consumed during the 4 week intervention phase. A total of about 12 ounces (administered in two small cans) of the juice will be consumed

    This is a novel dietary supplement.

07

What researchers measure

Primary outcomes

  1. Safety of the Dietary Intervention

    Safety will be evaluated by monitoring adverse events throughout the study. Information will be collected through routine study assessments, including participant interactions, diary entries, vital signs, and standard clinical laboratory testing. Adverse events will be graded using the Common Terminology Criteria for Adverse Events (CTCAE v.5.0). For this study, we define a dose-limiting toxicity (DLT) as the appearance of any adverse event reaching Grade 3-5 toxicity or that otherwise prevents continuation of the intervention. Adverse events will be graded using established clinical criteria, and the number and severity of events observed during the intervention period will be summarized to determine the rate of dose-limiting toxicities

    Time frame: From enrollment to the end of treatment at 8 weeks

  2. Assessment of Compliance With the Dietary Intervention (soy)

    Participant adherence to the dietary intervention will be monitored using daily self-report diaries, where individuals record how much of the study beverage they consumed each day. These entries will be used to assess overall adherence across the intervention period without disclosing any specific targets or thresholds to participants. In addition to self-reports, the study will also evaluate biological markers of dietary intake. Levels of compounds derived from the soy components of the beverage (isoflavone metabolites)) will be measured in urine collected before and after the intervention.

    Time frame: From enrollment to the end of treatment at 8 weeks

  3. Assessment of Compliance With the Dietary Intervention (lycopene)

    Description: In addition to self-reports and assessment of soy metabolites, investigators will also evaluate biological markers of dietary intake. Levels of compounds derived from the lycopene components of the beverage will be measured in plasma collected before and after the intervention.

    Time frame: From enrollment to the end of treatment at 8 weeks

Secondary outcomes

  1. Determine the Change in Inflammatory Marker Levels

    Changes in circulating inflammatory markers will be evaluated before and after the dietary intervention. Concentrations (pg/mL) of key markers (Interleukin-5, Interleukin-1beta, Tumor Necrosis Factor-alpha) will be measured using standard laboratory techniques to characterize overall shifts in inflammation-related signaling. The analysis will help determine whether the intervention is associated with measurable changes in the body's inflammatory profile over time.

    Time frame: From enrollment to the end of treatment at 8 weeks

Other outcomes

  1. Determine the Change in Physical Activity Levels

    Physical activity will be evaluated at two points during the study using a validated wearable activity monitor. The amount of daily activity, expressed in minutes, will be analyzed as a continuous measure. This assessment provides an estimate of both sedentary behavior and ambulatory movement in real-world settings, allowing us to characterize overall patterns of physical activity during the trial.

    Time frame: From enrollment to the end of treatment at 8 weeks

  2. Determine the Change in Average Abdominal Pain Score

    Changes in abdominal pain will be evaluated throughout the study. Pain intensity will be measured at each study visit and through daily participant diaries using the standard numeric rating scale (range of 0-10; higher value represents higher pain intensity). This approach provides a simple, widely used quantitative measure of abdominal discomfort, allowing us to track overall patterns of pain over the course of the trial

    Time frame: From enrollment to the end of treatment at 8 weeks

  3. Determine the Change in Quality of Life

    Quality of life will be assessed at multiple time points using a validated questionnaire specific to pancreatitis (Pancreatitis Quality of Life, PANQOLI). Overall scores on this scale range from 0 to 103, with higher scores indicating a better quality of life. Changes from baseline in the overall composite score will be evaluated to understand how participants' quality-of-life experiences shift over the course of the study.

    Time frame: From enrollment to the end of treatment at 8 weeks

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Apr 2026 (actual). Primary completion is estimated for Jan 2028, 21 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 20, 2026: start Feb 2026 → Apr 2026 and primary completion Nov 2027 → Jan 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2026
First posted
Mar 3, 2026
StartActual
Apr 2, 2026was Feb 2026
Primary completionEst.
Jan 14, 2028was Nov 2027
CompletionEst.
Jun 1, 2028
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Feb 2026→Apr 2, 2026 (actual)
Oct 20, 2026
Primary completion
Nov 2027→Jan 14, 2028
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Start date Feb 2026→Apr 2, 2026 (now actual)
    Primary completion Nov 2027→Jan 14, 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07447687
Responsible party
Philip Hart (Physician, Ohio State University) — Principal investigator
First posted
Mar 3, 2026
Start date
Apr 2, 2026
Primary completion
Jan 14, 2028 (estimated)
Completion
Jun 1, 2028 (estimated)
Last update
Oct 20, 2026

Study contacts

Spencer Harris
Contact
spencer.harris@osumc.edu
614-293-6255

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion